Novel magnetic/ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment

Neuro-Oncology

Volumn 12, Issue 10, 2010, Pages 1050-1060

  Chen, Pin Yuan ^a   Liu, Hao Li ^a,b   Hua, Mu Yi ^a   Yang, Hung Wei ^a   Huang, Chiung Yin ^a   Chu, Po Chun ^a   Lyu, Lee Ang ^a   Tseng, I Chou ^a   Feng, Li Ying ^a   Tsai, Hong Chieh ^a   Chen, Shu Mei ^a   Lu, Yu Jen ^a   Wang, Jiun Jie ^a   Yen, Tzu Chen ^b   Ma, Yunn Hwa ^c   Wu, Tony ^a   Chen, Jyh Ping ^a   Chuang, Jih Ing ^d   Shin, Jyh Wei ^d   Hsueh, Chuen ^a   Wei, Kuo Chen ^a   more..

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

BCNU; Glioma; Magnetic nanoparticle; MRI; Ultrasound

Indexed keywords

CARMUSTINE; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CONTROLLED STUDY; DIFFUSION; DRUG DELIVERY SYSTEM; GLIOMA; MAGNETIC FIELD; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL CHEMISTRY; RAT; ULTRASOUND;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CARMUSTINE; DRUG DELIVERY SYSTEMS; GLIOMA; HIGH-ENERGY SHOCK WAVES; MAGNETIC RESONANCE IMAGING; MAGNETICS; MALE; NANOPARTICLES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 78449242559     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq054     Document Type: Article

References (40)

1. Lin SH, Kleinberg LR. Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther. 2008;8:343-359.
2. Pan E, Mitchell SB, Tsai JS. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neurooncol. 2008;88:353-357.
3. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114-123.
4. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21:2683-2710.
5. Parney IF, Chang SM. Current chemotherapy for glioblastoma. Cancer J. 2003;9:149-156.
6. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther. 2004;104:29-45.
7. Neuwelt EA. Mechanisms of disease: the blood-brain barrier. Neurosurgery. 2004;54:131-140.
8. Karkan D, Pfeifer C, Vitalis TZ, et al. A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier. PLoS ONE. 2008;3:e2469.
9. Suidan GL, McDole JR, Chen Y, Pirko I, Johnson AJ. Induction of blood brain barrier tight junction protein alterations by CD8 T cells. PLoS One. 2008;3:e3037.
10. Monsky WL, Fukumura D, Gohongi T, et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. 1999;59:4129-4135.
11. Doolittle ND, Miner ME, Hall WA, et al. Safety and efficacy of a multicenter study using intra-arterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer. 2000;88:637-647.
12. Pardridge WM. Neurotrophins, neuroprotection and the blood-brain barrier. Curr Opin Investig Drugs. 2002;3:1753-1757.
13. Pardridge WM. Targeting neurotherapeutic agents through the blood- brain barrier. Arch Neurol. 2002;59:35-40.
14. Rautioa J, Chikhale PJ. Drug delivery systems for brain tumor therapy. Curr Pharm Des. 2004;10:1341-1353.
15. Alexiou C, ArnoldW, Klein RJ, et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 2000;60:6641-6648.
16. Koo YE, Reddy GR, Bhojani M, et al. Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev. 2006;58:1556-1577.
17. Chertok B, David AE, Huang Y, Yang VC. Glioma selectivity of magnetically targeted nanoparticles: a role of abnormal tumor hydrodynamics. J Control Release. 2007;122:315-323.
18. Chertok B, Moffat BA, David AE, et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials. 2008;29:487-496.
19. Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology. 2001;220:640-646.
20. Mesiwala AH, Farrell L, Wenzel HJ, et al. High-intensity focused ultrasound selectively disrupts the blood-brain barrier in vivo. Ultrasound Med Biol. 2002;28:389-400.
21. Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA. Non-invasive opening of BBB by focused ultrasound. Acta Neurochir. 2003;86(suppl.):555-558.
22. Hynynen K, McDannold N, Sheikov NA, Jolesz FA, Vykhodtseva N. Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. NeuroImage. 2005;24:12-20.
23. McDannold N, Vykhodtseva N, Raymond S, Jolesz FA, Hynynen K. MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits. Ultrasound Med Biol. 2005;31:1527-1537.
24. Liu H-L, Hua M-Y, Chen P-Y, et al. Blood-brain barrier disruption by focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology. 2010;255:415-425.
25. Loo TL, Dion RL. Colorimetric method for the determination of 1,3-bis(2-chloroethyl)-1-nitrosourea. J Pharm Sci. 1965;54:809-810.
26. Kim GY, Tyler BM, Tupper MM, et al. Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model. J Control Release. 2007;123:172-178.
27. Magnitsky S, Watson DJ, Walton RM, et al. In vivo and ex vivo MRI detection of localized and disseminated neural stem cell grafts in the mouse brain. NeuroImage. 2005;26:744-754.
28. Arosarena O, Guerin C, Brem H, Laterra J. Endothelial differentiation in intracerebral and subcutaneous experimental gliomas. Brain Res. 1994;640:98-104. (Pubitemid 24086535)
29. Blasberg RG, Molnar P, Horowitz M, Kornblith P, Pleasants R, Fenstermacher J. Regional blood flow in RT-9 brain tumors. J Neurosurg. 1983;58:863-873.
30. Pathak AP, Schmainda KM, Ward BD, Linderman JR, Rebro KJ, Greene AS. MR-derived cerebral blood volume maps: issues regarding histological validation and assessment of tumor angiogenesis. Magn Reson Med. 2001;46:735-747.
31. Pulfer SK, Gallo JM. Enhanced brain tumor selectivity of cationic magnetic polysaccharide microspheres. J Drug Target. 1998;6:215-227.
32. Lesniak MS, Brem H. Targeted therapy for brain tumours. Nat Rev Drug Discov. 2004;3:499-508.
33. Groothuis DR, Fischer JM, Lapin G, Vick NA, Bigner DD. Permeability of different experimental brain tumor models to horseradish peroxidase. J Neuropathol Exp Neurol. 1982;41:164-185.
34. Neuwelt EA, Barnett PA, Bigner DD, Frenkel EP. Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. Proc Natl Acad Sci USA. 1982;79:4420-4423.
35. Neuwelt EA, Frenkel EP, D'Agostino AN. Growth of human lung tumor in the brain of the nude rat as a model to evaluate antitumor agent delivery across the blood-brain barrier. Cancer Res. 1985;45:2827-2833.
36. Neuwelt EA, Howieson J, Frenkel EP, et al. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery. 1986;19:573-582.
37. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271-284.
38. Huang B-R, Chen P-Y, Huang C-Y, et al. Bioavailability of magnetic nanoparticles to the brain. J Magn Magn Mater. 2009;321:1604-1609.
39. Fulci G, Dmitrieva N, Gianni D, et al. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res. 2007;67:9398-9406.
40. Okada H, Kohanbash G, Zhu X, et al. Immunotherapeutic approaches for glioma. Crit Rev Immunol. 2009;29:1-42.